Metabolic Adaptation in Heart Failure and the Role of Ketone Bodies as Biomarkers.

IF 3.8 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Current Heart Failure Reports Pub Date : 2024-10-01 Epub Date: 2024-09-07 DOI:10.1007/s11897-024-00678-6

Michael W Foster, Joshua M Riley, Praneet C Kaki, Amine Al Soueidy, Ehson Aligholiazadeh, J Eduardo Rame

{"title":"Metabolic Adaptation in Heart Failure and the Role of Ketone Bodies as Biomarkers.","authors":"Michael W Foster, Joshua M Riley, Praneet C Kaki, Amine Al Soueidy, Ehson Aligholiazadeh, J Eduardo Rame","doi":"10.1007/s11897-024-00678-6","DOIUrl":null,"url":null,"abstract":"Purpose of review: The development and progression of heart failure is characterized by metabolic and physiologic adaptations allowing patients to cope with cardiac insufficiency. This review explores the changes in metabolism in heart failure and the potential role of biomarkers, particularly ketone bodies, in staging and prognosticating heart failure progression.Recent findings: Recent insights into myocardial metabolism shed light on the heart's response to stress, highlighting the shift towards reliance on ketone bodies as an alternative fuel source. Elevated blood ketone levels have been shown to correlate with the severity of cardiac dysfunction, emphasizing their potential as prognostic indicators. Furthermore, studies exploring therapeutic interventions targeting specific metabolic pathways offer promise for improving outcomes in heart failure. Ketones have prognostic utility in heart failure, and potentially, an avenue for therapeutic intervention. Challenges remain in deciphering the optimal balance between metabolic support and exacerbating cardiac remodeling. Future research endeavors must address these complexities to advance personalized approaches in managing heart failure.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"498-503"},"PeriodicalIF":3.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11415519/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Heart Failure Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11897-024-00678-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The development and progression of heart failure is characterized by metabolic and physiologic adaptations allowing patients to cope with cardiac insufficiency. This review explores the changes in metabolism in heart failure and the potential role of biomarkers, particularly ketone bodies, in staging and prognosticating heart failure progression.

Recent findings: Recent insights into myocardial metabolism shed light on the heart's response to stress, highlighting the shift towards reliance on ketone bodies as an alternative fuel source. Elevated blood ketone levels have been shown to correlate with the severity of cardiac dysfunction, emphasizing their potential as prognostic indicators. Furthermore, studies exploring therapeutic interventions targeting specific metabolic pathways offer promise for improving outcomes in heart failure. Ketones have prognostic utility in heart failure, and potentially, an avenue for therapeutic intervention. Challenges remain in deciphering the optimal balance between metabolic support and exacerbating cardiac remodeling. Future research endeavors must address these complexities to advance personalized approaches in managing heart failure.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

心力衰竭的代谢适应和酮体作为生物标记物的作用。

综述的目的：心力衰竭的发生和发展以代谢和生理适应为特征，使患者能够应对心功能不全。这篇综述探讨了心力衰竭时新陈代谢的变化以及生物标志物（尤其是酮体）在心力衰竭分期和预后中的潜在作用：最近对心肌新陈代谢的深入研究揭示了心脏对压力的反应，突出了依赖酮体作为替代燃料来源的转变。血液酮体水平的升高已被证明与心功能不全的严重程度相关，强调了其作为预后指标的潜力。此外，针对特定代谢途径的治疗干预研究也为改善心力衰竭的预后带来了希望。酮体对心力衰竭有预后作用，并有可能成为治疗干预的途径。要在新陈代谢支持和加重心脏重塑之间取得最佳平衡，仍然存在挑战。未来的研究工作必须解决这些复杂问题，以推进管理心力衰竭的个性化方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Heart Failure Reports Medicine-Emergency Medicine

CiteScore

5.30

自引率

0.00%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of heart failure. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as investigative, pharmacologic, and nonpharmacologic therapies, pathophysiology, and prevention. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.

期刊最新文献

Cardiogenic Shock: Focus on Non-Cardiac Biomarkers. Biomarkers of Hemodynamic Congestion in Heart Failure. Heart Failure in Rheumatoid Arthritis: Clinical Implications. Screening for Heart Failure: Biomarkers to Detect Heightened Risk in the General Population. Troponin Elevation in Asymptomatic Cancer Patients: Unveiling Connections and Clinical Implications.